Data, Outcomes, and Quality (DOQ)

DOQ Home

Surveys and Data Collection Systems >>

Behavioral Health Prevalence Data (NSDUH) Emergency Room Data (DAWN) Facilities Data (N-SSATS) Treatment Data (TEDS)

Publications >>

Single-Topic Short Reports Data Spotlights Topical, Multi-Survey Data Reviews Methodology Reports Topical Analytical Reports State and Metro Reports Other Mental Health Statistics Reports

Data Access >>

Public-Use Data Files (SAMHDA) Request Data

Links >>

Reports by Topic FAQ Evidence-Based Programs (NREPP)

View Reports By Topic >>

A-B »

•Adderall®

•Adolescents

•ADHD Stimulant Medications

•ADSS (Alcohol & Drug Services Study)

•Adults

•Adverse Reactions

•Alcohol

	•Alcohol dependence
	•Alcohol problems
	•Alcohol treatment

•Amphetamines

•Analgesics

•Benzodiazepines

•Binge drinking

•Buprenorphine

C »

C
	•Children and families •Church/Faith-based activities •Cigarettes, Cigars (see tobacco) •Cities / urban areas •Cocaine/crack cocaine •Comorbidity/Co-occurring disorders •Costs of treatment •Cough medicine •Criminal justice system

D »

•DASIS (Drug Abuse Services Information System)

•DAWN (Drug Abuse Warning Network)

•Depression

•Detox/Detoxification

•Dextromethorphan®

• Driving under the Influence; Driving While Intoxicated (DUI/DWI)

•Drug Services Research Survey (DSRS)

•Drugs

	•Drug Dependence
	•Drug Problems
	•Drug Treatment

•Drug brand / generic names

•Drug names: Pronunciation

•Drug Services Research Survey

•DSRS (Drug Services Research Survey)

•DUI/DWI

E-H »

E
	•Ecstasy (MDMA) •Elderly/Older adults •Emergency Department visits
F
	•Females •Flunitrazapam (see sedatives)
G
	•Gender •GHB (Gamma Hydroxy Butyrate) •Generic/brand drug names
H
	•Hallucinogens •Hashish (see Marijuana) •Health insurance •Heavy drinking •Heroin •Hydrocodone (see analgesics)

I-L »

I
	•Inhalants •Inhalation drug use •Inpatient treatment •Injection drug use •Insurance
J

K
	•Ketamine
L	•LAAM •Licensing regulations and drinking •LSD

M-N »

M
	•Marijuana /hashish •MDMA (Ecstasy) •Mental health •Methadone •Methamphetamine
N
	•Nicotine •Nonmedical use of prescription drugs •Non response report •NSDUH/NHSDA •N-SSATS

O-Q »

O
	•Older Adults •Opiates •Outpatient treatment •Over-the-Counter drugs •Oxycodone •Oxycontin®
P
	•Pain relievers •PCP •Perceived Risk •Peyote •Pregnant/recent mothers •Prescription drugs
Q

R »

•Racial & ethnic groups:

•African Americans

•Alaskan Natives

•American Indians

•Asians

•Blacks

•Hispanics

•Latinas/Latinos

•Pacific Islanders

•Whites/Caucasians

•Regions

•Residential treatment

•Ritalin®

•Rohypnol ®

•Rural/urban areas

S »

S
	•Salvia divinorum (see hallucinogens) •Sedatives •Special studies •Specific drugs •Speed/Amphetamine •SROS (Services Research Outcome Study) •State data •Stimulants •Substance Use •Sub State data •Suicide •Support

T-Z »

T
	•TEDS • Tobacco (Cigarettes, cigars, smokeless tobacco) •Tranquilizers •Treatment Locator
U
	•Urban/rural areas
V
	•Veterans •Violence
W
	•Women
X
	•XTC (see Ecstasy/MDMA)
Y
	•Young Adults (18-25 years of age) •Youth (under 17 years of age)
Z